BACKGROUND AND OBJECTIVE: Research on the negative impact of gastro-oesophageal reflux disease (GORD) on the health-related quality of life (HR-QOL) and resource utilization of patients with persistent and intense GORD symptoms despite proton pump inhibitor (PPI) therapy is lacking. The aim of this study was to describe the population of patients with GORD with persistent moderate-to-severe symptoms despite ongoing PPI therapy, and to compare their HR-QOL and healthcare resource use with patients with low GORD symptom load during ongoing PPI therapy. METHODS: In this post hoc analysis of the 2007 National Health and Wellness Survey (NHWS), PPI-compliant (≥22 days with PPI use in the past month) European (France, Germany and the UK) and US respondents with physician-diagnosed GORD were stratified into those with persistent and intense GORD symptoms, those with low symptom load, or an intermediate group. RESULTS: 5672 PPI-compliant respondents were identified (persistent and intense symptoms, n = 1741; low symptom load, n = 1805; intermediate group, n = 2126). Respondents with persistent and intense symptoms had poorer HR-QOL than patients with a low symptom load, but none of the differences were statistically significant. Respondents with persistent and intense symptoms also reported lower work productivity (all countries; significant difference [p < 0.01] only in the US), greater activity impairment (all countries; significant difference [p < 0.01] only in the US) and more hours missed from work due to health problems (US, UK and Germany; significant difference [p < 0.01] only in the US). In the UK and US, respondents with persistent and intense symptoms reported significantly more visits to both primary-care physicians and specialists than respondents with a low symptom load (all p < 0.01). Additionally, US respondents with persistent and intense symptoms reported significantly more emergency room visits (p < 0.01). CONCLUSION: The 2007 NHWS gives support to the hypothesis that persistent and intense GORD symptoms despite PPI therapy have a significant and negative impact on both HR-QOL and healthcare resource utilization. These findings outline the need for new treatment options for symptomatic GORD patients taking PPI therapy.
BACKGROUND AND OBJECTIVE: Research on the negative impact of gastro-oesophageal reflux disease (GORD) on the health-related quality of life (HR-QOL) and resource utilization of patients with persistent and intense GORD symptoms despite proton pump inhibitor (PPI) therapy is lacking. The aim of this study was to describe the population of patients with GORD with persistent moderate-to-severe symptoms despite ongoing PPI therapy, and to compare their HR-QOL and healthcare resource use with patients with low GORD symptom load during ongoing PPI therapy. METHODS: In this post hoc analysis of the 2007 National Health and Wellness Survey (NHWS), PPI-compliant (≥22 days with PPI use in the past month) European (France, Germany and the UK) and US respondents with physician-diagnosed GORD were stratified into those with persistent and intense GORD symptoms, those with low symptom load, or an intermediate group. RESULTS: 5672 PPI-compliant respondents were identified (persistent and intense symptoms, n = 1741; low symptom load, n = 1805; intermediate group, n = 2126). Respondents with persistent and intense symptoms had poorer HR-QOL than patients with a low symptom load, but none of the differences were statistically significant. Respondents with persistent and intense symptoms also reported lower work productivity (all countries; significant difference [p < 0.01] only in the US), greater activity impairment (all countries; significant difference [p < 0.01] only in the US) and more hours missed from work due to health problems (US, UK and Germany; significant difference [p < 0.01] only in the US). In the UK and US, respondents with persistent and intense symptoms reported significantly more visits to both primary-care physicians and specialists than respondents with a low symptom load (all p < 0.01). Additionally, US respondents with persistent and intense symptoms reported significantly more emergency room visits (p < 0.01). CONCLUSION: The 2007 NHWS gives support to the hypothesis that persistent and intense GORD symptoms despite PPI therapy have a significant and negative impact on both HR-QOL and healthcare resource utilization. These findings outline the need for new treatment options for symptomatic GORD patients taking PPI therapy.
Authors: Guy E Boeckxstaens; Hanneke Beaumont; Veerle Mertens; Hans Denison; Magnus Ruth; John Adler; Debra G Silberg; Daniel Sifrim Journal: Gastroenterology Date: 2010-05-05 Impact factor: 22.682
Authors: Peter J Kahrilas; John Dent; Karsten Lauritsen; Peter Malfertheiner; Hans Denison; Stefan Franzén; Goran Hasselgren Journal: Clin Gastroenterol Hepatol Date: 2007-10-22 Impact factor: 11.382
Authors: Choo Hean Poh; Anita Gasiorowska; Tomas Navarro-Rodriguez; Marcia R Willis; Deborah Hargadon; North Noelck; Jane Mohler; Christopher S Wendel; Ronnie Fass Journal: Gastrointest Endosc Date: 2010-01 Impact factor: 9.427
Authors: P Wahlqvist; M Karlsson; D Johnson; J Carlsson; S C Bolge; M-A Wallander Journal: Aliment Pharmacol Ther Date: 2008-02-29 Impact factor: 8.171
Authors: Samer El-Dika; Gordon H Guyatt; David Armstrong; Alessio Degl'innocenti; Ingela Wiklund; Carlo A Fallone; Lisa Tanser; Sander Veldhuyzen van Zanten; Diane Heels-Ansdell; Peter Wahlqvist; Naoki Chiba; Alan N Barkun; Peggy Austin; Holger J Schünemann Journal: BMC Gastroenterol Date: 2005-07-10 Impact factor: 3.067
Authors: Daniel Skubleny; Noah J Switzer; Jerry Dang; Richdeep S Gill; Xinzhe Shi; Christopher de Gara; Daniel W Birch; Clarence Wong; Matthew M Hutter; Shahzeer Karmali Journal: Surg Endosc Date: 2016-12-15 Impact factor: 4.584
Authors: Rebeca Dominguez-Profeta; Joslin N Cheverie; Rachel R Blitzer; Arielle M Lee; Lauren McClain; Ryan C Broderick; Bryan J Sandler; Garth R Jacobsen; Santiago Horgan; David C Kunkel Journal: Surg Endosc Date: 2020-10-30 Impact factor: 4.584
Authors: Heather F Warren; Jessica L Reynolds; John C Lipham; Joerg Zehetner; Nikolai A Bildzukewicz; Paul A Taiganides; Jody Mickley; Ralph W Aye; Alexander S Farivar; Brian E Louie Journal: Surg Endosc Date: 2015-11-05 Impact factor: 4.584